Physician profile
Jose Castillo
NPI 1245223478
$4,258.52
in general payments reported to CMS, 2019-2025
26 companies · $68.49 in 2025
The $68.49 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,016 · 2020: $374 · 2021: $647 · 2022: $977 · 2023: $478 · 2024: $697 · 2025: $68.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,075 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,075.25 |
| Education | $168.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $926.73 | 2019-2024 | Opdivo, Krazati |
| Astrazeneca Pharmaceuticals LP | $339.37 | 2019-2025 | Imfinzi |
| Amgen INC. | $291.54 | 2019-2020 | |
| Exelixis INC. | $290.98 | 2019-2022 | |
| Seagen INC. | $284.80 | 2021-2023 | Adcetris |
| Jazz Pharmaceuticals INC. | $269.89 | 2021-2022 | |
| Beigene USA, INC. | $263.10 | 2022-2024 | Brukinsa |
| Genentech USA, INC. | $224.18 | 2019 | |
| Sanofi-Aventis U.S. LLC | $197.95 | 2019-2020 | |
| Glaxosmithkline, LLC. | $184.57 | 2021-2022 | |
| Janssen Biotech, INC. | $122.40 | 2019 | |
| Pfizer INC. | $118.44 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $94.85 | 2019 | |
| Gilead Sciences, INC. | $93.82 | 2021-2023 | Trodelvy |
| Mirati Therapeutics, INC. | $92.48 | 2024 | Krazati |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $87.07 | 2022 | |
| Astellas Pharma US INC | $80.78 | 2024 | Padcev |
| Karyopharm Therapeutics INC. | $80.45 | 2022 | |
| Alexion Pharmaceuticals, INC. | $55.15 | 2022 | |
| Celgene Corporation | $34.28 | 2024 | Reblozyl |
| Abbvie INC. | $30.12 | 2024 | |
| Daiichi Sankyo INC. | $25.90 | 2024 | Enhertu |
| Sobi, INC | $22.08 | 2023 | |
| Novartis Pharmaceuticals Corporation | $19.04 | 2022 | |
| Shionogi INC | $15.97 | 2019 | |
| Incyte Corporation | $12.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.